EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Comparison of timing of relapse in dogs with nonassociative immune-mediated hemolytic anemia, thrombocytopenia, or polyarthritis

Richard Sparrow iD, James W Swann iD, Barbara Glanemann iD

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.17004 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2024. Written by Richard Sparrow and 2 co-authors. Institution: Department of Clinical Science and Services, Royal Veterinary College, Hatfield, UK. Major MEDLINE topics: Dog Diseases, Anemia, Hemolytic, Autoimmune, Thrombocytopenia, Arthritis. Cited 11 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Relapse is a clinical concern in dogs diagnosed with immune-mediated hemolytic anemia (IMHA), thrombocytopenia (ITP), or polyarthritis (IMPA). The average time to relapse is unknown, and evidence that vaccination is associated with disease relapse is lacking. Hypothesis/Objectives Compare the incidence of relapse in groups of dogs with IMHA, ITP, or IMPA over a 24-month period after diagnosis and compare proportions of dogs that received vaccines in those dogs that did and did not relapse. Animals One hundred sixty client-owned dogs (73 with IMHA, 55 with ITP, 32 with IMPA).

Methods

Medical records of dogs were reviewed with the goal of following cases for a minimum of 2 years. Incidence of relapse was calculated for each disease, and relapse rates in dogs that were or were not vaccinated after diagnosis were compared.

Results

Relapse rates at 12 months differed significantly among disease groups (P = .02), with a higher rate for IMPA (35%) compared to IMHA (11%) or ITP (11%). Relapse rate at 24 months was 41% for IMPA, 18% for IMHA, and 23% for ITP. Ninety percent of IMPA relapses occurred in the first 12 months after diagnosis, compared with 56% for IMHA and 50% for ITP. Vaccine administration after diagnosis was not associated with relapse (P = .78). Conclusions and Clinical Importance Risk of disease relapse in IMPA is highest in the first year after diagnosis, with a higher relapse rate compared with IMHA and ITP. The role of vaccination in disease relapse remains unclear.

Subjects

MeSH terms (MEDLINE)

Dog DiseasesAnemia, Hemolytic, AutoimmuneThrombocytopeniaArthritisOrganophosphorus CompoundsHumansDogsAnimalsRecurrence

Author keywords

autoimmunecanineidiopathicvaccination

Substances

isopropyl methylphosphonic acidOrganophosphorus Compounds

Authors and institutions

  • Department of Clinical Science and Services, Royal Veterinary College, Hatfield, UK.
  • Columbia Stem Cell Initiative, Columbia University, New York, New York, USA.

ORCID profiles: Richard Sparrow, James W Swann, Barbara Glanemann

Cite

APA

Sparrow, R., Swann, J. W., & Glanemann, B. (2024). Comparison of timing of relapse in dogs with nonassociative immune-mediated hemolytic anemia, thrombocytopenia, or polyarthritis. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17004

Vancouver

Sparrow R, Swann JW, Glanemann B. Comparison of timing of relapse in dogs with nonassociative immune-mediated hemolytic anemia, thrombocytopenia, or polyarthritis. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17004

BibTeX
@article{Sparrow2024,
  author = {Sparrow, Richard and Swann, James W and Glanemann, Barbara},
  title = {Comparison of timing of relapse in dogs with nonassociative immune-mediated hemolytic anemia, thrombocytopenia, or polyarthritis},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.17004}
}
Start for free →